Therapeutic gene correction of HBB frameshift CD41-42 (-TCTT) deletion in human hematopoietic stem cells

Abstract

Β-thalassemia is one of the global health burdens. The CD41-42 (-TCTT) mutation at HBB is the most prevalent pathogenic mutation of β-thalassemia in both China and Southeast Asia. Previous studies focused on repairing the HBB CD41-42 (-TCTT) mutation in β-thalassemia patient-specific induced pluripotent stem cells, which were subsequently differentiated into hematopoietic stem and progenitor cells (HSPCs) for transplantation. In this study, we directly applied the CRISPR/Cas9-based gene editing therapy to correct the HBB CD41-42 (-TCTT) mutation in patient-derived HSPCs. The effective editing induced by Cas9:sgRNA ribonucleoprotein and single-stranded oligodeoxynucleotides (ssODNs) was confirmed in HUDEP-2 cell lines harboring the HBB CD41-42 (-TCTT) mutation. Further correction of heterozygote and homozygote HBB CD41-42 (-TCTT) mutations in patient-derived HSPCs resulted in a 13.4–40.8% increase in the proportion of HBB-expressing (HBB+) cells following erythroid differentiation in vitro. At 16 weeks post-xenotransplantation of the edited HSPCs into coisogenic immunodeficient mice, the reparation efficiency in engrafted bone marrow was 17.21%±3.66%. Multiparameter flow cytometric analysis of the engrafted bone marrow showed an increase in the percentage of HBB+cells without impairing the ability of engraftment, self-renewal, and multilineage hematopoietic repopulation of HSPCs. For the safety evaluation, 103 potential off-target sites were predicted by SITE-seq and CRISPOR, with one site displaying significant off-target editing. Since this off-target site is located in the intergenic region, it is presumed to pose minimal risk. Taken together, our study provides critical preclinical data supporting the safety and efficacy of the gene therapy approach for HBB CD41-42 (-TCTT) mutation.

Keywords

Gene editing therapy / β-thalassemia / HBB CD41-42 (-TCTT) / CRISPR/Cas9 / Hematopoietic stem and progenitor cells

References

[1] Adachi K, Konitzer P, Pang J, Reddy KS, Surrey S. Amino Acids Responsible for Decreased 2, 3-Biphosphosphoglycerate Binding to Fetal Hemoglobin. Blood. 1997, 90(8): 2916-2920

[2] Allen, D., Kalter, N., Rosenberg, M., & Hendel, A. (2023). Homology-Directed-Repair-Based Genome Editing in HSPCs for the Treatment of Inborn Errors of Immunity and Blood Disorders. Pharmaceutics, 15(5). https://doi.org/10.3390/pharmaceutics15051329

[3] Andreani, M., Testi, M., Gaziev, J., Condello, R., Bontadini, A., Tazzari, P. L., . . . Lucarelli, G. (2011). Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica, 96(1), 128–133. https://doi.org/10.3324/haematol.2010.031013

[4] Azhagiri MKK, Babu P, Venkatesan V, Thangavel S. Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy. Stem Cell Res Ther. 2021, 12(1): 500

[5] Cameron, P., Fuller, C. K., Donohoue, P. D., Jones, B. N., Thompson, M. S., Carter, M. M., . . . May, A. P. (2017). Mapping the genomic landscape of CRISPR-Cas9 cleavage. Nat Methods, 14(6), 600–606. https://doi.org/10.1038/nmeth.4284

[6] Canver MC, Orkin SH. Customizing the genome as therapy for the beta-hemoglobinopathies. Blood. 2016, 127(21): 2536-2545

[7] Cao A, Kan YW. The prevention of thalassemia. Cold Spring Harb Perspect Med. 2013, 3(2) a011775

[8] Charlesworth, C. T., Camarena, J., Cromer, M. K., Vaidyanathan, S., Bak, R. O., Carte, J. M., . . . Porteus, M. H. (2018). Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting. Molecular Therapy - Nucleic Acids, 12, 89–104. https://doi.org/10.1016/j.omtn.2018.04.017

[9] Clement, K., Rees, H., Canver, M. C., Gehrke, J. M., Farouni, R., Hsu, J. Y., . . . Pinello, L. (2019). CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol, 37(3), 224–226. https://doi.org/10.1038/s41587-019-0032-3

[10] Concordet JP, Haeussler M. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018, 46(W1): W242-W245

[11] Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., . . . Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819–823. https://doi.org/10.1126/science.1231143

[12] Cosenza LC, Gasparello J, Romanini N, Zurlo M, Zuccato C, Gambari R, Finotti A. Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β039-thalassemia patients. Molecular Therapy - Methods & Clinical Development. 2021, 21: 507-523

[13] Dalwadi DA, Calabria A, Tiyaboonchai A, Posey J, Naugler WE, Montini E, Grompe M. AAV integration in human hepatocytes. Mol Ther. 2021, 29(10): 2898-2909

[14] De Dreuzy, E., Heath, J., Zuris, J. A., Sousa, P., Viswanathan, R., Scott, S., . . . Chang, K.-H. (2019). EDIT-301: An Experimental Autologous Cell Therapy Comprising Cas12a-RNP Modified mPB-CD34+ Cells for the Potential Treatment of SCD. Blood, 134(Supplement_1), 4636–4636. https://doi.org/10.1182/blood-2019-130256

[15] Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., . . . Porteus, M. H. (2016). CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature, 539(7629), 384–389. https://doi.org/10.1038/nature20134

[16] DeWitt, M. A., Magis, W., Bray, N. L., Wang, T., Berman, J. R., Urbinati, F., . . . Corn, J. E. (2016). Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med, 8(360), 360ra134. https://doi.org/10.1126/scitranslmed.aaf9336

[17] Ferrari, S., Jacob, A., Beretta, S., Unali, G., Albano, L., Vavassori, V., . . . Naldini, L. (2020). Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat Biotechnol, 38(11), 1298–1308. https://doi.org/10.1038/s41587-020-0551-y

[18] Ferrari, S., Jacob, A., Cesana, D., Laugel, M., Beretta, S., Varesi, A., . . . Naldini, L. (2022). Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell Stem Cell, 29(10), 1428–1444 e1429. https://doi.org/10.1016/j.stem.2022.09.001

[19] Ferrari, S., Jacob, A., Cesana, D., Laugel, M., Beretta, S., Varesi, A., . . . Naldini, L. (2022). Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell Stem Cell, 29(10), 1428–1444.e1429. https://doi.org/10.1016/j.stem.2022.09.001

[20] Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., . . . Corbacioglu, S. (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N Engl J Med, 384(3), 252–260. https://doi.org/10.1056/NEJMoa2031054

[21] Frangoul, H., Locatelli, F., Bhatia, M., Mapara, M. Y., Molinari, L., Sharma, A., . . . Grupp, S. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Blood, 140(Supplement 1), 29–31. https://doi.org/10.1182/blood-2022-162353

[22] Fu, B., Liao, J., Chen, S., Li, W., Wang, Q., Hu, J., . . . Wu, Y. (2022). CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric beta(0)/beta(0) transfusion-dependent beta-thalassemia. Nat Med, 28(8), 1573–1580. https://doi.org/10.1038/s41591-022-01906-z

[23] Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010, 5: 11

[24] Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., . . . Lebwohl, D. (2021). CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med, 385(6), 493–502. https://doi.org/10.1056/NEJMoa2107454

[25] Gu, T., Ju, C., Sun, H., Gao, X., Zhang, M., Yu, W., . . . Zhao, J. (2022). Abstract 5621: NCG-X mouse: A novel animal model to evaluate preclinical studies of humanized erythroid reconstitution without irradiation. Cancer Research, 82(12_Supplement), 5621–5621. https://doi.org/10.1158/1538-7445.Am2022-5621

[26] Han, L., He, H., Yang, Y., Meng, Q., Ye, F., Chen, G., & Zhang, J. (2021). Distinctive Clinical and Pathologic Features of Immature Teratomas Arising From Induced Pluripotent Stem Cell Injection in a Patient With Type 2 Diabetes. https://doi.org/10.21203/rs.3.rs-580493/v1

[27] Hoban, M. D., Cost, G. J., Mendel, M. C., Romero, Z., Kaufman, M. L., Joglekar, A. V., . . . Kohn, D. B. (2015). Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood, 125(17), 2597–2604. https://doi.org/10.1182/blood-2014-12-615948

[28] Huang SZ, Zhou XD, Zhu H, Ren ZR, Zeng YT. Detection of beta-thalassemia mutations in the Chinese using amplified DNA from dried blood specimens. Hum Genet. 1990, 84(2): 129-131

[29] Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012, 337(6096): 816-821

[30] Kass EM, Jasin M. Collaboration and competition between DNA double-strand break repair pathways. FEBS Lett. 2010, 584(17): 3703-3708

[31] Kimura A, Matsunaga E, Takihara Y, Nakamura T, Takagi Y, Lin S, Lee H. Structural analysis of a beta-thalassemia gene found in Taiwan. J Biol Chem. 1983, 258(5): 2748-2749

[32] King, A. A., Kamani, N., Bunin, N., Sahdev, I., Brochstein, J., Hayashi, R. J., . . . Shenoy, S. (2015). Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol, 90(12), 1093–1098. https://doi.org/10.1002/ajh.24183

[33] Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018, 36(8): 765-771

[34] Kountouris P, Lederer CW, Fanis P, Feleki X, Old J, Kleanthous M. IthaGenes: an interactive database for haemoglobin variations and epidemiology. PLoS ONE. 2014, 9(7) e103020

[35] Kurita, R., Suda, N., Sudo, K., Miharada, K., Hiroyama, T., Miyoshi, H., . . . Nakamura, Y. (2013). Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. PLoS One, 8(3), e59890. https://doi.org/10.1371/journal.pone.0059890

[36] Lai K, Huang G, Su L, He Y. The prevalence of thalassemia in mainland China: evidence from epidemiological surveys. Sci Rep. 2017, 7(1)): 920

[37] Langer, A. L. (1993). Beta-Thalassemia. In M. P. Adam, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. W. Gripp, & A. Amemiya (Eds.), GeneReviews((R)). Seattle (WA).

[38] Laosombat, V., Wongchanchailert, M., Sattayasevana, B., Wiriyasateinkul, A., & Fucharoen, S. (2001). Clinical and hematologic features of beta0-thalassemia (frameshift 41/42 mutation) in Thai patients. Haematologica, 86(2), 138–141. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11224481

[39] Leibowitz, M. L., Papathanasiou, S., Doerfler, P. A., Blaine, L. J., Sun, L., Yao, Y., . . . Pellman, D. (2021). Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. Nat Genet, 53(6), 895–905. https://doi.org/10.1038/s41588-021-00838-7

[40] Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., . . . Huang, J. (2015). CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell, 6(5), 363–372. https://doi.org/10.1007/s13238-015-0153-5

[41] Lieber MR. The mechanism of human nonhomologous DNA end joining. J Biol Chem. 2008, 283(1): 1-5

[42] Liu, Y., Yang, Y., Kang, X., Lin, B., Yu, Q., Song, B., . . . Fan, Y. (2017). One-Step Biallelic and Scarless Correction of a beta-Thalassemia Mutation in Patient-Specific iPSCs without Drug Selection. Mol Ther Nucleic Acids, 6, 57–67. https://doi.org/10.1016/j.omtn.2016.11.010

[43] Liu, R., Xu, H., Liang, J., Xie, W., Yang, G., Shi, L., . . . Lai, Y. (2022). Preliminary Result of the Safety and Efficacy of Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells (RM-001) in Transfusion-Dependent Βeta-Thalassemia. Blood, 140(Supplement 1), 4915–4916. https://doi.org/10.1182/blood-2022-169151

[44] Locatelli, F., Lang, P., Li, A., Corbacioglu, S., de la Fuente, J., Wall, D. A., . . . Frangoul, H. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. Blood, 140(Supplement 1), 4899–4901. https://doi.org/10.1182/blood-2022-166881

[45] Locatelli, F., Thompson, A. A., Kwiatkowski, J. L., Porter, J. B., Thrasher, A. J., Hongeng, S., . . . Walters, M. C. (2022). Betibeglogene Autotemcel Gene Therapy for Non-beta(0)/beta(0) Genotype beta-Thalassemia. N Engl J Med, 386(5), 415–427. https://doi.org/10.1056/NEJMoa2113206

[46] Magrin, E., Semeraro, M., Hebert, N., Joseph, L., Magnani, A., Chalumeau, A., . . . Cavazzana, M. (2022). Long-term outcomes of lentiviral gene therapy for the beta-hemoglobinopathies: the HGB-205 trial. Nat Med, 28(1), 81–88. https://doi.org/10.1038/s41591-021-01650-w

[47] Miccio, A., Cesari, R., Lotti, F., Rossi, C., Sanvito, F., Ponzoni, M., . . . Ferrari, G. (2008). In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A, 105(30), 10547–10552. https://doi.org/10.1073/pnas.0711666105

[48] Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010, 11(3): 196-207

[49] Nahmad, A. D., Reuveni, E., Goldschmidt, E., Tenne, T., Liberman, M., Horovitz-Fried, M., . . . Barzel, A. (2022). Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage. Nat Biotechnol, 40(12), 1807–1813. https://doi.org/10.1038/s41587-022-01377-0

[50] Nguyen, G. N., Everett, J. K., Kafle, S., Roche, A. M., Raymond, H. E., Leiby, J., . . . Sabatino, D. E. (2020). A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nature Biotechnology, 39(1), 47–55. https://doi.org/10.1038/s41587-020-0741-7

[51] Niu, X., He, W., Song, B., Ou, Z., Fan, D., Chen, Y., . . . Sun, X. (2016). Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in beta-Thalassemia-induced Pluripotent Stem Cells. J Biol Chem, 291(32), 16576–16585. https://doi.org/10.1074/jbc.M116.719237

[52] Papapetrou EP. Gene and Cell Therapy for beta-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier. Adv Exp Med Biol. 2017, 1013: 219-240

[53] Park, S. H., Lee, C. M., Dever, D. P., Davis, T. H., Camarena, J., Srifa, W., . . . Bao, G. (2019). Highly efficient editing of the beta-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Nucleic Acids Res, 47(15), 7955–7972. https://doi.org/10.1093/nar/gkz475

[54] Pavel-Dinu, M., Wiebking, V., Dejene, B. T., Srifa, W., Mantri, S., Nicolas, C. E., . . . Porteus, M. H. (2019). Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat Commun, 10(1), 1634. https://doi.org/10.1038/s41467-019-09614-y

[55] Shin, J. J., Schroder, M. S., Caiado, F., Wyman, S. K., Bray, N. L., Bordi, M., . . . Corn, J. E. (2020). Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells. Cell Rep, 32(9), 108093. https://doi.org/10.1016/j.celrep.2020.108093

[56] Smith, A. R., Schiller, G. J., Vercellotti, G. M., Kwiatkowski, J. L., Krishnamurti, L., Esrick, E. B., . . . Walters, M. C. (2019). Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia. Blood, 134(Supplement_1), 3544–3544. https://doi.org/10.1182/blood-2019-125743

[57] Suchy, F. P., Karigane, D., Nakauchi, Y., Higuchi, M., Zhang, J., Pekrun, K., . . . Nakauchi, H. (2024). Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors. Nature Biotechnology. https://doi.org/10.1038/s41587-024-02171-w

[58] Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia Lancet. 2018, 391(10116): 155-167

[59] Taher AT, Musallam KM, Cappellini MD. beta-Thalassemias. N Engl J Med. 2021, 384(8): 727-743

[60] Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J. A., Hongeng, S., . . . Cavazzana, M. (2018). Gene Therapy in Patients with Transfusion-Dependent beta-Thalassemia. N Engl J Med, 378(16), 1479–1493. https://doi.org/10.1056/NEJMoa1705342

[61] Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., . . . Behlke, M. A. (2018). A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med, 24(8), 1216–1224. https://doi.org/10.1038/s41591-018-0137-0

[62] Wei, D., Li, Y., Li, C., Peng, Z., Zhao, Y., Zhang, W., . . . Fang, R. (2019). Manufacturing Scale-up and Preclinical Development of ET-01, Autologous CD34+ Cells with the BCL11A Erythroid Enhancer Edited By CRISPR/Cas9, for Patients with β-Thalassemia Major. Blood, 134(Supplement_1), 965–965. https://doi.org/10.1182/blood-2019-126499

[63] Wen, J., Cao, T., Wu, J., Chen, Y., Zhi, S., Huang, Y., . . . Huang, J. (2022). Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis. Mol Ther, 30(1), 164–174. https://doi.org/10.1016/j.ymthe.2021.05.010

[64] Wienert B, Martyn GE, Funnell APW, Quinlan KGR, Crossley M. Wake-up Sleepy Gene: Reactivating Fetal Globin for beta-Hemoglobinopathies. Trends Genet. 2018, 34(12): 927-940

[65] Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., . . . Bauer, D. E. (2019). Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med, 25(5), 776–783. https://doi.org/10.1038/s41591-019-0401-y

[66] Xian, Y., Xie, Y., Song, B., Ou, Z., Ouyang, S., Xie, Y., . . . Sun, X. (2020). The safety and effectiveness of genetically corrected iPSCs derived from beta-thalassaemia patients in nonmyeloablative beta-thalassaemic mice. Stem Cell Res Ther, 11(1), 288. https://doi.org/10.1186/s13287-020-01765-w

[67] Yang, Y., Zhang, X., Yi, L., Hou, Z., Chen, J., Kou, X., . . . Gao, S. (2016). Naive Induced Pluripotent Stem Cells Generated From beta-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9. Stem Cells Transl Med, 5(1), 8–19. https://doi.org/10.5966/sctm.2015-0157

[68] Yang, F., Wang, Y., Wang, Q., Pang, J., Liu, G., Yang, Y., . . . Wu, Y. (2023). Efficient repair of human genetic defect by CRISPR/Cas9-mediated interlocus gene conversion. Life Medicine, 2(5). https://doi.org/10.1093/lifemedi/lnad042

[69] Zhang, W., Cai, W. W., Zhou, W. P., Li, H. P., Li, L., Yan, W., . . . Xu, X. M. (2008). Evidence of gene conversion in the evolutionary process of the codon 41/42 (-CTTT) mutation causing beta-thalassemia in southern China. J Mol Evol, 66(5), 436–445. https://doi.org/10.1007/s00239-008-9096-2

[70] Zittersteijn HA, Harteveld CL, Klaver-Flores S, Lankester AC, Hoeben RC, Staal FJT, Goncalves M. A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies. Front Genome Ed. 2020, 2 617780

RIGHTS & PERMISSIONS

The Author(s)